NSE BSE
marksans pharma limited stock

MARKSANS PHARMA LIMITED Share Price

- - (%)
Sector: -

10579

524404

MARKSANS

img img img img
No Data Available

MARKSANS PHARMA LIMITED : Share Price Update


As of the latest trading session, MARKSANS PHARMA LIMITED share price is currently at 168.55, which is up by 3.69 from its previous closing. Today, the stock has fluctuated between 163.65 and 169.35. Over the past year, MARKSANS PHARMA LIMITED has achieved a return of 118.34 %. In the last month alone, the return has been -6.70 %.

MARKSANS PHARMA LIMITED Performance

Day Range

Low163.65 High169.35
168.95

52 Week Range

Low 70.55 High 185.50
168.95

Open Price

165.65

Prev. Close

164.85

Volume (Shares)

1200616.00

Total traded value

2028.44

Upper Circuit

197.80

Lower Circuit

131.90

Note: The current prices & values are delayed, Login to your account for live updates.

MARKSANS PHARMA LIMITED Fundamentals


(Standalone)

Market Cap (Cr) 7638.07
PE Ratio (TTM) 62.94
Book Value / Share 25.68
Beta 0.97
ROE 10.85%
EPS (TTM) 2.62
Dividend Yield 0.30%
Net Profit Qtr (Cr) 25.29

MARKSANS PHARMA LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars DEC 2023 (Values in Cr)
Revenue 241.36
Operating Expense 208.09
Net Profit 25.29
Net Profit Margin (%) 10.47
Earnings Per Share (EPS) 0.56
EBITDA 43.30
Effective Tax Rate (%) 26.90
Particulars SEP 2023 (Values in Cr)
Revenue 204.67
Operating Expense 176.10
Net Profit 31.29
Net Profit Margin (%) 15.28
Earnings Per Share (EPS) 0.69
EBITDA 53.23
Effective Tax Rate (%) 29.68
Particulars JUN 2023 (Values in Cr)
Revenue 182.04
Operating Expense 160.26
Net Profit 44.19
Net Profit Margin (%) 24.27
Earnings Per Share (EPS) 0.98
EBITDA 59.37
Effective Tax Rate (%) 18.75
Particulars MAR 2023 (Values in Cr)
Revenue 153.05
Operating Expense 134.51
Net Profit 17.81
Net Profit Margin (%) 11.63
Earnings Per Share (EPS) 0.43
EBITDA 27.02
Effective Tax Rate (%) 22.05
Particulars DEC 2022 (Values in Cr)
Revenue 172.75
Operating Expense 153.96
Net Profit 25.62
Net Profit Margin (%) 14.83
Earnings Per Share (EPS) 0.63
EBITDA 39.53
Effective Tax Rate (%) 25.73
Particulars MAR 2023 (Values in Cr)
Revenue 655.20
Operating Expense 583.65
Net Profit 102.87
Net Profit Margin (%) 15.70
Earnings Per Share (EPS) 2.48
EBITDA 152.39
Effective Tax Rate (%) 22.09
Particulars MAR 2022 (Values in Cr)
Revenue 658.29
Operating Expense 566.04
Net Profit 103.99
Net Profit Margin (%) 15.79
Earnings Per Share (EPS) 2.54
EBITDA 155.97
Effective Tax Rate (%) 22.68
Particulars MAR 2021 (Values in Cr)
Revenue 599.55
Operating Expense 506.38
Net Profit 98.38
Net Profit Margin (%) 16.40
Earnings Per Share (EPS) 2.40
EBITDA 144.87
Effective Tax Rate (%) 20.87
Particulars MAR 2020 (Values in Cr)
Revenue 433.42
Operating Expense 380.86
Net Profit 37.90
Net Profit Margin (%) 8.74
Earnings Per Share (EPS) 0.93
EBITDA 71.66
Effective Tax Rate (%) 28.10
Particulars MAR 2019 (Values in Cr)
Revenue 424.16
Operating Expense 376.08
Net Profit 43.62
Net Profit Margin (%) 10.28
Earnings Per Share (EPS) 1.07
EBITDA 71.26
Effective Tax Rate (%) 22.12
Particulars MAR 2023 (Values in Cr)
Book Value / Share 38.51
ROE % 18.00
ROCE % 21.77
Total Debt to Total Equity 0.08
EBITDA Margin 21.52
Particulars MAR 2022 (Values in Cr)
Book Value / Share 27.10
ROE % 17.89
ROCE % 22.83
Total Debt to Total Equity 0.07
EBITDA Margin 20.17
Particulars MAR 2021 (Values in Cr)
Book Value / Share 21.66
ROE % 31.34
ROCE % 38.77
Total Debt to Total Equity 0.04
EBITDA Margin 25.16
Particulars MAR 2020 (Values in Cr)
Book Value / Share 15.54
ROE % 20.49
ROCE % 25.02
Total Debt to Total Equity 0.11
EBITDA Margin 16.98
Particulars MAR 2019 (Values in Cr)
Book Value / Share 13.25
ROE % 14.86
ROCE % 17.23
Total Debt to Total Equity 0.22
EBITDA Margin 13.68
Particulars MAR 2023 (Values in Cr)
Book Value / Share 24.52
ROE % 10.85
ROCE % 14.11
Total Debt to Total Equity 0.01
EBITDA Margin 23.26
Particulars MAR 2022 (Values in Cr)
Book Value / Share 16.90
ROE % 15.02
ROCE % 19.45
Total Debt to Total Equity 0.02
EBITDA Margin 23.69
Particulars MAR 2021 (Values in Cr)
Book Value / Share 14.65
ROE % 17.29
ROCE % 22.04
Total Debt to Total Equity 0.02
EBITDA Margin 24.16
Particulars MAR 2020 (Values in Cr)
Book Value / Share 12.35
ROE % 7.07
ROCE % 10.19
Total Debt to Total Equity 0.09
EBITDA Margin 16.53
Particulars MAR 2019 (Values in Cr)
Book Value / Share 11.50
ROE % 8.18
ROCE % 10.14
Total Debt to Total Equity 0.16
EBITDA Margin 16.80
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 714.96
Total Assets 2190.38
Total Liabilities 2190.38
Total Equity 1765.07
Share Outstanding 453163746
Price to Book Ratio 2.87
Return on Assets (%) 12.15
Return on Capital (%) 14.74
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 349.26
Total Assets 1640.10
Total Liabilities 1640.10
Total Equity 1222.97
Share Outstanding 409313698
Price to Book Ratio 2.70
Return on Assets (%) 11.25
Return on Capital (%) 14.6
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 212.28
Total Assets 1228.25
Total Liabilities 1228.25
Total Equity 905.35
Share Outstanding 409313698
Price to Book Ratio 3.41
Return on Assets (%) 19.42
Return on Capital (%) 25.81
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 93.72
Total Assets 902.66
Total Liabilities 902.66
Total Equity 649.12
Share Outstanding 409313698
Price to Book Ratio 1.13
Return on Assets (%) 13.37
Return on Capital (%) 18.08
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 33.53
Total Assets 803.70
Total Liabilities 803.70
Total Equity 552.69
Share Outstanding 409313698
Price to Book Ratio 2.16
Return on Assets (%) 9.51
Return on Capital (%) 11.72
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 440.26
Total Assets 1344.86
Total Liabilities 1344.86
Total Equity 1111.32
Share Outstanding 453163746
Price to Book Ratio 2.87
Return on Assets (%) 7.64
Return on Capital (%) 9.26
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 224.04
Total Assets 965.60
Total Liabilities 965.60
Total Equity 784.67
Share Outstanding 409313698
Price to Book Ratio 2.70
Return on Assets (%) 10.76
Return on Capital (%) 13.17
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 105.61
Total Assets 740.69
Total Liabilities 740.69
Total Equity 599.71
Share Outstanding 409313698
Price to Book Ratio 3.41
Return on Assets (%) 13.28
Return on Capital (%) 16.4
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 3.35
Total Assets 599.78
Total Liabilities 599.78
Total Equity 505.62
Share Outstanding 409313698
Price to Book Ratio 1.13
Return on Assets (%) 6.31
Return on Capital (%) 7.5
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 1.80
Total Assets 611.98
Total Liabilities 611.98
Total Equity 470.57
Share Outstanding 409313698
Price to Book Ratio 2.16
Return on Assets (%) 7.12
Return on Capital (%) 7.96
Particulars MAR 2023 (Values in Cr)
Net Income 337.65
Cash from Operations 300.42
Cash from Investing -259.21
Cash from Financing 197.82
Net change in Cash 176.02
Free Cash Flow 354.05
Particulars MAR 2022 (Values in Cr)
Net Income 247.51
Cash from Operations 172.11
Cash from Investing -84.39
Cash from Financing 79.51
Net change in Cash 94.37
Free Cash Flow 218.44
Particulars MAR 2021 (Values in Cr)
Net Income 302.16
Cash from Operations 227.12
Cash from Investing -44.84
Cash from Financing -15.28
Net change in Cash 118.45
Free Cash Flow 273.54
Particulars MAR 2020 (Values in Cr)
Net Income 157.17
Cash from Operations 258.32
Cash from Investing -59.58
Cash from Financing -113.55
Net change in Cash 60.18
Free Cash Flow 318.23
Particulars MAR 2019 (Values in Cr)
Net Income 104.30
Cash from Operations 54.39
Cash from Investing -13.47
Cash from Financing -20.77
Net change in Cash -6.86
Free Cash Flow 67.54
Particulars MAR 2023 (Values in Cr)
Net Income 132.03
Cash from Operations 83.34
Cash from Investing -194.62
Cash from Financing 210.01
Net change in Cash 67.12
Free Cash Flow 118.62
Particulars MAR 2022 (Values in Cr)
Net Income 134.50
Cash from Operations 87.80
Cash from Investing -128.06
Cash from Financing 70.86
Net change in Cash -1.23
Free Cash Flow 110.65
Particulars MAR 2021 (Values in Cr)
Net Income 124.33
Cash from Operations 127.13
Cash from Investing 8.87
Cash from Financing -13.53
Net change in Cash 102.26
Free Cash Flow 148.13
Particulars MAR 2020 (Values in Cr)
Net Income 52.72
Cash from Operations 118.06
Cash from Investing -24.14
Cash from Financing -81.87
Net change in Cash 1.55
Free Cash Flow 142.47
Particulars MAR 2019 (Values in Cr)
Net Income 56.01
Cash from Operations 32.66
Cash from Investing -20.20
Cash from Financing 0.95
Net change in Cash 0.56
Free Cash Flow 56.12
Company Name Price P/E P/B Market Cap 52 Week Low/High
MARKSANS PHARMA LIMITED 164.90 23.56 3.98 7472.67 70.20 / 185.40
BLISS GVS PHARMA LTD 109.15 11.93 1.18 1142.70 71.00 / 148.95
CIPLA LTD 1420.05 26.93 4.29 114654.12 911.80 / 1519.00
FERMENTA BIOTECH LIMITED 160.95 0.00 1.65 473.69 132.30 / 214.00
GLAXOSMITHKLINE PHARMA LT 2023.85 53.46 22.26 34285.24 1265.00 / 2649.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
MARKSANS PHARMA LIMITED 164.90 62.94 6.42 7472.67 70.20 / 185.40
AMRUTAJAN HEALTH LTD 749.30 49.23 8.26 2166.27 556.05 / 802.60
ASTRAZENECA PHARMA IND LT 5639.25 88.39 21.52 14098.13 3131.10 / 7208.00
BLISS GVS PHARMA LTD 109.15 15.08 1.15 1142.70 71.00 / 148.95
ABBOTT INDIA LIMITED 26545.40 46.96 15.25 56408.98 20594.25 / 29628.15

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 161.50
  • 26 Days 163.10
  • 10 Days 161.90
  • 50 Days 159.60
  • 12 Days 162.40
  • 100 Days 159.00
  • 20 Days 164.80
  • 200 Days 112.10
163.67
PIVOT
First Resistance 168.53
Second Resistance 172.22
Third Resistance 177.08
First Support 159.98
Second Support 155.12
Third Support 151.43
RSI 47.34
MACD -0.77
Commodity Channel Index (CCI) -9.48
ADX 17.61
Williams % R -42.22

Over 1 Month

down

-6.70

Over 3 Months

down

-1.19

Over 6 Months

down

17.12

Over 1 Year

down

118.34

Over 3 Years

down

31.80

Over 5 Years

down

50.57

MARKSANS PHARMA LIMITED Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

MARKSANS PHARMA LIMITED Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
36.34
Promoter Holdings
43.84
FII
15.57
DII
4.22
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Mark Saldanha Shareholding of Promoter and Promoter Group 1.98491553E8 43.8
Orbimed Asia Iv Mauritius Fvci Limited Public Shareholding 4.9324324E7 10.88
Quant Mutual Fund - Quant Small Cap Fund Public Shareholding 1.2641259E7 2.79
Sandra Saldanha Shareholding of Promoter and Promoter Group 220180.0 0.05

MARKSANS PHARMA LIMITED

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-06-07 0.5 Final 2023-06-07 Equity shares 2022-08-19 0.25 Final 2022-08-23 Equity shares 2021-09-15 0.25 Final 2021-09-17 Equity shares 2020-09-22 0.1 Final 2020-09-24 Equity shares 2019-09-19 0.05 Final 2019-09-21 Equity shares 2018-09-19 0.05 Final 2018-09-22 Equity shares 2017-09-19 0.05 Final 2017-09-21 Equity shares 2016-09-22 0.12 Final 2016-09-24 Equity shares 2015-09-23 0.12 Final 2015-09-26 Equity shares 2014-09-18 0.1 Final 2014-09-20 Equity shares
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date
2008-03-11 10.0 1.0 2008-03-18

Learn More About Stocks

About MARKSANS PHARMA LIMITED

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by MARKSANS PHARMA LIMITED

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 5x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Marksans Pharma Ltd?

Answer Field

The share price of Marksans Pharma Ltd for NSE is ₹ 168.55 and for BSE is ₹ 169.2.

What is the Market Cap of Marksans Pharma Ltd?

Answer Field

The market cap of Marksans Pharma Ltd for NSE is ₹ 7,638.07 Cr. and for BSE is ₹ 7,667.53 Cr. as of now.

What is the 52 Week High and Low of Marksans Pharma Ltd?

Answer Field

The 52 Week High and Low of Marksans Pharma Ltd for NSE is ₹ 185.50 and ₹ 70.55 and for BSE is ₹ 185.40 and ₹ 70.20.

How to Buy Marksans Pharma Ltd share?

Answer Field

You can trade in Marksans Pharma Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Marksans Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 118.34%.

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

7 Lac+ Users

icon-with-text

4.3 App Rating

icon-with-text

4 Languages

icon-with-text

₹ 3800 Cr MTF Book

icon-with-text
loader